David F. McDermott

Brigham and Women's Hospital — United States

Medicine · Health Sciences

109h-index88.0kcitations1.1kworks3.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(600), Renal cell carcinoma treatment(558), Cancer Genomics and Diagnostics(187), CAR-T cell therapy research(186), Renal and related cancers(166)

Publications1.1k total

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers
CA A Cancer Journal for Clinicians·2025Open Access
Figure S6 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Table S2 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Supplementary Data from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Table S3 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Figure S11 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Figure S10 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Figure S7 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Figure S1 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Figure S12 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Figure S8 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Table S1 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Figure S2 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Figure S9 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Figure S5 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Figure S4 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Figure S3 from Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma
2025Open Access
Phase 1 LITESPARK-001 study of belzutifan in participants with advanced solid tumors: results of the glioblastoma expansion cohort
Neuro-Oncology Advances·2025· 2 citedOpen Access
Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma 3574
The Journal of Immunology·2025Open Access
Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium
The Lancet Oncology·2025· 4 citedOpen Access
page 1 of 54Next →

Frequent Co-authors

Michael B. Atkins(21), Toni K. Choueiri(21), F. Stephen Hodi(18), Brian I. Rini(13), Mario Sznol(11), Robert J. Motzer(9), Jeffrey A. Sosman(8), Thomas Powles(8), Elizabeth R. Plimack(8), Jedd D. Wolchok(7), John D. Powderly(7), Bernard Escudier(7), Hans J. Hammers(7), Julie R. Brahmer(6), Priti S. Hegde(6), Igor Puzanov(6), Christian Kollmannsberger(6), Frede Donskov(6), Howard Gurney(6), Sabina Signoretti(6)